EXPANDING
FOR BETTER
TREATMENT
OPTIONS
IMPACT 2010-2016
1
hepatitis C
direct-acting
antiviral
100+
ongoing
pharmaceutical
development projects
12
HIV medicines and an
HIV technology platform
licensed
Vision, Mission,
Governance and Model
The vision of the MPP is a world
in which people in low- and
middle-income countries have rapid
access to affordable and appropriate
HIV, hepatitis C and tuberculosis
treatments.
HIV
In 2016, the MPP moved to expand
existing HIV licensing agreements
and ramp up its work with generic
manufacturing partners to bring
MPP-licensed antiretrovirals
to market.
Hepatitis C
Ten companies are now licensed to
produce daclatasvir, with the MPP
adding three new licensees in 2016,
Beximco, Sandoz and Zydus Cadila, to
manufacture the treatment.
Tuberculosis
TB Alliance and the MPP signed a
Memorandum of Understanding in
April outlining a collaboration to
encourage the development
of new TB regimens.
Product Development
& Technical Expertise
With its manufacturing partners, the
MPP continued to intensify its efforts
to expedite the development of
generic versions of hepatitis C and
HIV medicines in 2016.
FINANCIAL STATEMENTS
For 2016
and Report of the Statutory Auditor.